(Q46963140)

26 December 2017

title

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study (English)

1 reference

26 December 2017

0 references

1 reference

1 reference

Rautio K

1

1 reference

26 December 2017

Tapanainen JS

series ordinal

2

1 reference

26 December 2017

Ruokonen A

series ordinal

3

1 reference

26 December 2017

Morin-Papunen LC

series ordinal

4

1 reference

26 December 2017

language of work or name

English

0 references

publication date

24 February 2006

1 reference

26 December 2017

published in

Human Reproduction

1 reference

26 December 2017

volume

21

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

1400-1407

1 reference

26 December 2017

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

The theoretical bases of indirect calorimetry: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Clinical assessment of body hair growth in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Cardiovascular risk in women with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Adipogenesis and obesity: rounding out the big picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI505

21 January 2018

Identifiers

DOI

10.1093/HUMREP/DEI505

1 reference

26 December 2017

1 reference

26 December 2017